This page shows the latest Emflaza news and features for those working in and with pharma, biotech and healthcare.
to treat the symptoms of DMD – called Emflaza (deflazacort) – last year.
but was rejected in the US, and novel steroid Emflaza (deflazacort) from Marathon Pharma.
saying its commercial operations were already in gear following the FDA’s approval of Emflaza (deflazacort) for DMD earlier this year.
Not just any drug mind you - a decades-old corticosterioid called Emflaza (deflazacort) that is available elsewhere for about $1, 500 per year.
Marathon Pharmaceuticals is facing a backlash over plans to launch its just-approved steroid drug Emflaza - available for decades - at the princely sum of $89, 000 a year for Duchenne muscular ... In response, Marathon has said it is "pausing its
Marathon Pharma’s Emflaza is first approved to treat all genetic forms of the condition. ... Marathon insists that Emflaza causes fewer side effects than prednisone and so warrants premium pricing.
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...